Roche is paying $700m upfront for rights to bexobrutideg, a BTK degrader that it says has potential across oncology, immunology and neurology.
UK offers meningitis jab to young people after outbreak
The UK government has responded to calls to broaden vaccinations for meningitis B, offering the jab to “thousands” of young people this summer.
